Genomic  	Genomic  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
to  	to  	 TO	O
improve  	improve  	 VB	O
outcome  	outcome  	 NN	O
and  	and  	 CC	O
individualize  	individualize  	 JJ	O
therapy  	therapy  	 NN	O
in  	in  	 IN	O
cancer 	cancer 	 NN	O
:  	:  	 :	O
the  	the  	 DT	O
paradigm  	paradigm  	 NN	O
of  	of  	 IN	O
childhood  	childhood  	 FW	O
acute  	acute  	 FW	O
lymphoblastic  	lymphoblastic  	 FW	B-NP
leukemia  	leukemia  	 FW	I-NP
Childhood  	Childhood  	 FW	I-NP
acute  	acute  	 FW	O
lymphoblastic  	lymphoblastic  	 FW	B-NP
leukemia  	leukemia  	 FW	I-NP
( 	( 	 -LRB-	O
ALL 	ALL 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
the  	the  	 DT	O
classic  	classic  	 JJ	B-NP
example  	example  	 NN	I-NP
for  	for  	 IN	I-NP
a  	a  	 DT	I-NP
drug-responsive  	drug-responsive  	 JJ	I-NP
malignancy 	malignancy 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
contemporary  	contemporary  	 JJ	B-NP
risk-directed  	risk-directed  	 JJ	I-NP
therapies  	therapies  	 NNS	I-NP
cure  	cure  	 VB	O
more  	more  	 JJR	O
than  	than  	 IN	O
80 	80 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
children  	children  	 NNS	O
with  	with  	 IN	O
ALL  	ALL  	 NNP	O
in  	in  	 IN	O
industrialized  	industrialized  	 JJ	O
countries 	countries 	 NNS	O
.  	.  	 .	O
Antileukemic  	Antileukemic  	 JJ	B-NP
medications 	medications 	 NN	I-NP
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
can  	can  	 MD	O
cause  	cause  	 VB	O
significant  	significant  	 JJ	O
adverse  	adverse  	 JJ	O
drug  	drug  	 NN	B-NP
reactions 	reactions 	 NNS	I-NP
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
some  	some  	 DT	O
children  	children  	 NNS	O
have  	have  	 VBP	O
leukemia  	leukemia  	 JJ	B-NP
cell  	cell  	 NN	I-NP
clones  	clones  	 NNS	I-NP
which  	which  	 WDT	O
are  	are  	 VBP	O
resistant  	resistant  	 VBN	O
to  	to  	 TO	O
current  	current  	 JJ	O
antileukemic  	antileukemic  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
As  	As  	 IN	O
ALL  	ALL  	 NNP	O
is  	is  	 VBZ	O
still  	still  	 RB	O
among  	among  	 IN	O
the  	the  	 DT	O
leading  	leading  	 JJ	O
causes  	causes  	 NNS	O
of  	of  	 IN	O
death  	death  	 NN	O
from  	from  	 IN	O
disease  	disease  	 NN	O
in  	in  	 IN	O
children  	children  	 NNS	O
aged  	aged  	 VBN	O
one  	one  	 CD	O
to  	to  	 TO	O
15  	15  	 CD	O
years 	years 	 NNS	O
,  	,  	 ,	O
further  	further  	 JJ	O
improvement  	improvement  	 NN	O
of  	of  	 IN	O
childhood  	childhood  	 NN	O
ALL  	ALL  	 NNP	O
therapy  	therapy  	 NN	O
is  	is  	 VBZ	O
urgently  	urgently  	 RB	O
needed 	needed 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
pharmacogenomics  	pharmacogenomics  	 NN	B-NP
is  	is  	 VBZ	O
to  	to  	 TO	O
elucidate  	elucidate  	 VB	O
functionally  	functionally  	 JJ	O
relevant  	relevant  	 JJ	O
genomic  	genomic  	 JJ	B-NP
determinants  	determinants  	 NN	I-NP
for  	for  	 IN	I-NP
drug  	drug  	 NN	I-NP
disposition  	disposition  	 NN	I-NP
and  	and  	 CC	O
response  	response  	 NN	O
in  	in  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
optimize  	optimize  	 VB	O
drug  	drug  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
based  	based  	 VBN	O
on  	on  	 IN	O
a  	a  	 DT	O
patient 	patient 	 NN	O
's  	's  	 POS	O
genomic  	genomic  	 JJ	B-NP
profile 	profile 	 NN	I-NP
.  	.  	 .	O
Pharmacogenomics  	Pharmacogenomics  	 NNP	B-NP
has  	has  	 VBZ	O
evolved  	evolved  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
of  	of  	 IN	O
single  	single  	 JJ	O
candidate  	candidate  	 NN	B-NP
genes  	genes  	 NNS	I-NP
to  	to  	 TO	O
large-scale  	large-scale  	 JJ	O
genome-wide  	genome-wide  	 JJ	B-NP
strategies 	strategies 	 NNS	I-NP
.  	.  	 .	O
Results  	Results  	 NNS	O
from  	from  	 IN	O
recent  	recent  	 JJ	O
pharmacogenomic  	pharmacogenomic  	 JJ	B-NP
investigations  	investigations  	 NNS	I-NP
in  	in  	 IN	O
children  	children  	 NNS	O
with  	with  	 IN	O
ALL  	ALL  	 NNP	O
hold  	hold  	 NN	B-NP
promise  	promise  	 NN	I-NP
to  	to  	 TO	O
improve  	improve  	 VB	O
ALL  	ALL  	 JJ	O
therapy  	therapy  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
near  	near  	 JJ	O
future 	future 	 NN	O
;  	;  	 :	O
and  	and  	 CC	O
can  	can  	 MD	O
serve  	serve  	 VB	O
as  	as  	 IN	O
a  	a  	 DT	O
model  	model  	 NN	O
to  	to  	 TO	O
improve  	improve  	 VB	O
drug  	drug  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
other  	other  	 JJ	O
malignancies  	malignancies  	 NN	O
as  	as  	 IN	O
well 	well 	 RB	O
.  	.  	 .	O
